STRO · Sutro Biopharma, Inc.

The thesis

Sutro Biopharma's cancer-drug case still rests on clinical data that does not arrive until 2027, and the shares have fallen below the prior note's $10.00 invalidation level: the adjusted close was $9.29 on 28 October 2026, 77.3% under the 52-week high of $40.91. The quarterly report expected around 6 November 2026 (date unconfirmed) and the first-half 2027 STRO-004 update settle the next phase.

The company met its third-quarter guidance for STRO-006, a next-generation ADC (antibody-drug conjugate) aimed at the ITGB6 protein. It announced first patient dosed on 21 October 2026 and guided initial clinical data to the second half of 2027. The shares did not respond: they closed at $11.46 on 15 October 2026 and at $9.29 on 28 October 2026.

The narrative is dead as a market story: the shares are down 61.6% over three months, and the 14-day relative strength index (a momentum gauge where readings under 30 are called oversold) was 19.7 on 28 October 2026. Company news carries no announcement that explains the latest decline. The rating stays at the coverage level because the one new fact, the dosing start, matches guidance already weighed.

Bullish and bearish views on Sutro Biopharma, Inc.

The bull case on Sutro Biopharma, Inc. (STRO), in brief: STRO-006 is now in the clinic. The bear case: The price fell through dosing news.

Bull case

• STRO-006 is now in the clinic. Sutro announced first patient dosed in the Phase 1 solid-tumour trial on 21 October 2026. That clears the main near-term operating item flagged in the previous note.
• Cash covers the clinical plan. Sutro reported $164.3 million of cash, equivalents and marketable securities at 30 June 2026 and guided funding into at least the second quarter of 2028 (second-quarter release, 12 August 2026).
• Analysts still rate it highly. Wedbush reiterated Outperform with a $60 price target on 15 October 2026, the day the shares closed at $11.46.
• Early STRO-004 activity was reported. The 12 August 2026 update described confirmed and unconfirmed partial responses to the tissue-factor-targeting ADC across 49 patients (data cutoff 24 July 2026), with more follow-up guided for the first half of 2027.
• A partnering push is staffed. Sutro named Lucas Donigian Senior Vice President, Business Development, effective 29 September 2026, and said it is seeking ADC platform collaborations. A signed deal would add cash without selling shares.

Bear case

• The price fell through dosing news. The close dropped from $11.46 on 15 October 2026 to $9.29 on 28 October 2026, across the 21 October 2026 first-patient announcement. Buyers did not respond to a milestone the company had guided.
• STRO-006 data is a year away. The company guided initial clinical data to the second half of 2027, later than the first-half 2027 STRO-004 update. Nothing on the STRO-006 program can be measured before then.
• Efficacy is thinly documented. The 12 August 2026 disclosure covered 49 patients across eight tumour types, and part of the responses were unconfirmed. The sample is too small to support a broad efficacy conclusion.
• Share supply has roughly doubled. Shares outstanding were 16,581,171 on 7 August 2026 (Form 10-Q), against 8,584,309 on 31 December 2025, after a first-half 2026 offering of 7,868,383 shares. An up-to-$100 million at-the-market program registered in June 2026 remains available.
• Revenue is lumpy. Collaboration revenue was $9.8 million in the second quarter of 2026 against $63.7 million a year earlier, mostly from Astellas.

Price setup

The adjusted daily close was $9.29 on 28 October 2026. That is 77.3% below the 52-week high of $40.91 and below the $10.00 round-number level that the previous note named as its invalidation level. The three-month change is -61.6%.

The 14-day relative strength index was 19.7 on 28 October 2026, down from 23.1 on 15 October 2026. Selling has continued while the reading sat in oversold territory, so the move has not yet shown exhaustion in this measure.

Crowding evidence is limited to supply and timing. The at-the-market program allows share sales into weakness, and any sales first appear in the next quarterly filing. The third-quarter report, expected around 6 November 2026 per a data-vendor estimate, falls inside the next 30 days. No insider transaction filings are reported in company news or recent filings.

Catalysts, next 30 days

• ~6 November 2026, est.: third-quarter 2026 results. The date is a vendor estimate; the company usually announces it a few weeks ahead. The report would show cash, any at-the-market share sales and updated program timing.
• 31 December 2026: end of the late-2026 window for the STRO-227 IND submission. This falls outside 30 days but turns on a filing for the wholly owned dual-payload program.
• ~30 June 2027, est.: end of the guided first-half 2027 window for the next STRO-004 update. Response denominators and longer follow-up test whether the early responses hold.

What would change the view

The case breaks if STRO-004 responses fail confirmation at the first-half 2027 update, if STRO-006 timing slips from the second-half 2027 data guidance, or if Sutro raises equity ahead of new data. The third-quarter filing would show whether at-the-market sales have already occurred at prices near $9. A daily close below $8.00 would extend the decline past the next round-number level under the current close.

A recovery above $10.00 on a daily close, together with a partnership announcement or STRO-004 data with longer follow-up, would weaken the bear reading.

What it trades with

Sutro trades on its own clinical and financing news. Collaboration revenue from Astellas ties the quarterly results to partner milestone timing. No peer correlation is measured here, and no theme cluster currently carries the name.